AstraZeneca’s Susan Galbraith To Lead Its Entire Cancer R&D

Takes on José Baselga’s Role

After more that 10 years at the firm, Susan Galbraith has taken on an expanded role heading up oncology R&D at AstraZeneca.

Following the death of José Baselga earlier this year, AstraZeneca has announced that Susan Galbraith will now lead its oncology R&D from initial discovery through late-stage development.

Galbraith had been leading AstraZeneca’s early-stage oncology R&D but will now also take on late-stage development responsibilities in cancer, joining...